



**Supplementary Materials**

**Table S1.** PubMed search strings.

<b>Search number</b>	<b>Query</b>	<b>Results</b>
2	((arthritis, rheumatoid[MeSH Major Topic]) OR (rheumatoid arthritis[Title]))	16 739
3	((cardiovascular[Title] OR heart[Title] OR hypertension[Title] OR atrial[Title] OR coronary[Title]))	163 368
4	((infection[Title] OR infections[Title]))	91 892
5	((lymphoma[Title] OR lymphomas[Title]))	21 457
6	(((((squamous cell carcinoma[Title] OR squamous cell carcinomas[Title] OR SCC[Title]))) OR ((basal cell carcinoma[Title] OR basal cell carcinomas[Title] OR BCC[Title]))) AND ("non-melanoma skin cancer"[Title] OR "non melanoma skin cancer"[Title]))	210
7	((prevalence[MeSH Major Topic]) OR (prevalence[Title]))	40 667
8	(((((risk factors[MeSH Major Topic]) OR (pathology[MeSH Major Topic])) OR (inflammation[MeSH Major Topic])) OR (risk factor[Title] OR risk factors[Title] OR pathology[Title] OR pathogenesis[Title] OR etiology[Title] OR inflammation[Title] OR inflammatory[Title] OR cause[Title] OR causes[Title] OR screening[Title]))))	230 721
9	((((((((((quality of life[MeSH Major Topic]) OR (pain[MeSH Major Topic])) OR (patient reported outcome measures[MeSH Major Topic])) OR (outcome assessment, health care[MeSH Major Topic])) OR (treatment outcome[MeSH Major Topic])) OR (fatal outcome[MeSH Major Topic])) OR (disability evaluation[MeSH Major Topic])) OR (economics, medical[MeSH Major Topic])) OR (medication adherence[MeSH Major Topic])) OR ("quality of life"[Title] OR "life quality"[Title] OR "outcome"[Title] OR "outcomes"[Title] OR "fatal"[Title] OR "death"[Title] OR "survival"[Title] OR "burden"[Title] OR "economic"[Title] OR "cost"[Title] OR "adherence"[Title] OR "persistence"[Title] OR "compliance"[Title] OR "management"[Title] OR "decision"[Title] OR "decisions"[Title] OR "impact"[Title] OR "impacts"[Title] OR "effect"[Title] OR "effects"[Title] OR "influence"[Title] OR "influences"[Title]))))	878 306
10	((((tumor necrosis factor inhibitors[MeSH Major Topic]) OR (tumour necrosis factor[tiab] OR tumour necrosis factors[Title] OR tumor necrosis factor[Title] OR tumor necrosis factors[Title] OR TNF[Title] OR adalimumab[Title] OR certolizumab[Title] OR golimumab[Title] OR etanercept[Title] OR infliximab[Title] OR biologic[Title] OR bDMARD[Title])))	16 825
11	((#2) AND (#3 OR #4 OR #5 OR #6)) AND (#7 OR #8 OR #9 OR #10)	<b>335</b>

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).